COMMUNIQUÉS West-GlobeNewswire

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas
17/07/2025
- Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients - Prolonged and Durable Complete Responses (CRs) Observed in Two of Ten Refractory Ewing Sarcoma Patients - Two Additional Patients Had Durable [...]
Tria Federal Expands VA Partnership with $174M Software Engineering & Development Award
17/07/2025
ARLINGTON, Va., July 17, 2025 (GLOBE NEWSWIRE) -- Tria Federal has received a $174 million contract award to provide expanded software engineering and development services to the Department of Veterans Affairs’ (VA) [...]
Fifty 1 Labs, Inc. (FITY) Sparks AI Breakthrough in Drug Repurposing: Subsidiary Fifty1 AI Labs Announces Strategic Partnership with Intent to Acquire BioSpark AI Technologies
17/07/2025
SEATTLE, July 17, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, LLC, an innovative subsidiary of Fifty 1 Labs, Inc. ( OTC: FITY ), is thrilled to announce a strategic partnership with an intent to acquire BioSpark [...]
RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD
17/07/2025
Acquisition contributes iCAD's commercial, technology, and regulatory capabilities The acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow [...]
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
17/07/2025
LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an [...]
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
17/07/2025
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the [...]
Adventure Awaits: Make-A-Wish® Central and Northern Florida Makes Jeremy’s Dream Come True with a Thrilling Mexican Sport Fishing Adventure
17/07/2025
Family to Embark on an Unforgettable Trip, Courtesy of Stan and Naomi Loomis ORLANDO, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- Make-A-Wish® Central and Northern Florida , in collaboration with Stan and Naomi Loomis, co- [...]
Philips Launches ECG AI Marketplace to Enhance Early Cardiac Diagnosis
17/07/2025
July 17, 2025 Anumana's FDA-cleared LEF algorithm becomes first certified third-party solution available through Philips’ ECG ecosystem CAMBRIDGE, Mass. — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health [...]
Dogecoin Cash Inc. (OTCQB: DOGP) Reports Preparation of Provisional Patent Application for “Dogecoin Protocol” Architecture
17/07/2025
Company evaluating technical architecture intended to support interoperability and programmability for Dogecoin Mesquite, NV, July 17, 2025 (GLOBE NEWSWIRE) -- Dogecoin Cash Inc. (OTCQB: DOGP) today reported that it is [...]
Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement
17/07/2025
ROCKVILLE, Md. and SUZHOU, China, July 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company ”), a global biopharmaceutical company dedicated [...]
Immuron - FY25 global sales exceed projection, up 49% on prior year
17/07/2025
Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior year June 2025 Quarter [...]
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
17/07/2025
Company to participate in investor conferences in July and August VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse [...]
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
17/07/2025
ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp. , a Cayman Islands exempted company and special [...]
Communiqué de presse : Sanofi annonce la prolongation de l’offre publique d’achat sur Blueprint
17/07/2025
Sanofi annonce la prolongation de l’offre publique d’achat sur Blueprint Paris, le 17 juillet 2025. Sanofi annonce aujourd'hui que Rothko Merger Sub, Inc., une filiale détenue à 100 % par Sanofi, a prolongé la date d' [...]
Press Release: Sanofi announces extension of Blueprint tender offer
17/07/2025
Sanofi announces extension of Blueprint tender offer Paris, July 17, 2025 . Sanofi today announces that Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, has extended the expiration date of its tender offer [...]
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
17/07/2025
Ad hoc announcement pursuant to Art. 53 LR Q2 net sales grew +11% (cc 1 , +12% USD) with core operating income 1 up +21% (cc, +20% USD) Sales growth driven by continued strong performance from Kisqali (+64% cc), [...]
Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
17/07/2025
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16, 2026, and will [...]
Nicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 millions d’euros pour les droits exclusifs du traitement du glaucome NCX 470 aux Etats-Unis et dans l’ensemble des territoires non-licenciés
17/07/2025
Communiqué de presse Nicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 millions d’euros pour les droits exclusifs du traitement du glaucome NCX 470 aux Etats-Unis et dans l’ensemble des territoires non [...]
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
17/07/2025
Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 million upfront, with total potential development [...]

Pages